Mnk Inhibitor Compounds for Cancer Pathway Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological inhibitors for MAP kinase interacting kinase (Mnk) have limited progress, and there is a significant need for compounds that specifically inhibit Mnk kinase activity, particularly in cancer pathways, with few effective Mnk inhibitors available for therapeutic use.
Innovation Solution
Development of compounds that inhibit or modulate Mnk activity, including stereoisomers and pharmaceutically acceptable salts, as candidate therapeutic agents for treating conditions like cancer, targeting the kinase activity of Mnk1 and Mnk2 to regulate cancer pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological inhibitors are used to target Mnk, then some inhibition activity is achieved, but the inhibitors have limited progress and few are available for therapeutic use
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular structures of Mnk inhibitors, including modifications to core scaffolds, substituent groups, and stereochemical configurations. This approach generates a series of compounds with optimized binding affinity and selectivity for Mnk, thereby improving therapeutic effectiveness while establishing a scalable synthesis platform for producing multiple inhibitor variants.
2Measurement precision
If specific Mnk inhibition is achieved, then cancer pathway regulation is improved, but the complexity of identifying effective compounds increases
Solution Approach 1:
The patent applies segmentation by dividing the Mnk inhibitor development into distinct structural modules: core scaffolds (e.g., pyrimidine, pyridine rings), substituent groups (various R1, R2, R3 positions), and stereochemical elements. This modular approach allows systematic optimization of specificity at each position while simplifying the screening process through structure-activity relationship (SAR) analysis of individual components.
Solution Approach 2:
The patent systematically varies molecular parameters including substituent types (halogen, alkyl, aryl groups), positional isomers, and stereochemistry to optimize Mnk specificity. This structured parameter exploration enables precise tuning of inhibitor selectivity while maintaining a manageable compound library for screening.
Data Source
Figure 1
AI summary
The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.